Agenda 2009

Agenda
Monday 14 September 2009
08.30
Registration & Coffee
09.15
Welcome by Host Sponsor
Andrea Isler, Relationship Manager, Issuer & Investor Relations
SIX Swiss Exchange AG
09.30
Finance & M&A Panel
Chair: Stephanie Léouzon, Managing Director Healthcare, Credit Suisse
Panellists: Kees Been, CEO, EnVivo Pharmaceuticals
Ansbert Gadicke, Managing Director, MPM Capital
Barbara Heller, CFO, Santhera Pharmaceuticals
David Colpman, Senior Vice President, Business Development, Shire Pharmaceuticals Group
10.30
“Hurry Up! Invest Slowly”
Chair: Genghis Lloyd-Harris, Partner, Abingworth
Panellists: Andrew Kay, CEO, Algeta
Lionel Carnot, Partner, Bay City Ventures
Roel Bulthuis,Head of Merck Serono Ventures, Merck Serono Ventures
Simon Meier, Investment Director, Roche Venture Fund
Philippe Lutz, CFO, Synosia Therapeutics
11.30
Partnering Panel
Chair: Dimitri Dimitriou, CEO, DyoDelta Biosciences
Panellists: Andrew Wood, Executive Director, Eli Lilly & Company
Rüdiger Weseloh, Senior Director Head Negotiation, Early Stage Licensing, Merck Serono SA
Esteban Pombo Villar, Head of Strategic Alliance Management EU, Novartis Pharma AG
Nigel Sheail, VP, Head of Roche Corporate Business Development, F. Hoffmann-La Roche Ltd
12.30
Networking Lunch
13.30
Company Presentations
Exchange Room Auditorium Room Decision Room
13.30
Clinuvel AG 4SC AG caprotec bioanalytics GmbH
13.45
Octoplus NV Algeta ASA Covagen AG
14.00
Silence Therapeutics plc Biotec Pharmacon ASA Elm Biotech
14.15
CytRx Corporation Biotie Therapies Corp Mellitech
14.30
Ascent Therapeutics Clavis Pharma PolPhag GmbH
14.45
tba Cylene Pharmaceuticals Spherotec GmbH
15.00
Innate Pharma SAS Diamyd Medical AB MicroBioChips
15.15
EnVivo Pharmaceuticals Santaris Pharma A/S Wnt Research AB
15.30
Akers Biosciences, Inc. MolMed S.p.A Immunocore
15.45
e-Therapeutics plc Action Pharma A/S UnibioScreen
16.00
Immune Targeting Systems AVIR Green Hills Biotechnology BioCis Pharma Ltd
16.15
Phytopharm plc ERYtech Pharma Provecs Medical GmbH
16.30
DeveloGen tba tba
16.45
     
17.00
Break
17.15-18.15
“Can Partnering Finance Biotech?”
Moderator: Adrian Dawkes, Managing Consultant, PharmaVentures Ltd
Panellists: Nicholas Adams, Vice President, Business Development, Antisoma Research Limited
Lubor Gaal, Executive Director, Head of Europe, Strategic Transaction Group, Bristol-Myer Squib
Prof. Malcolm Young, CEO, e-Therapeutics
Margaret Beer, Senior Director and Head Licensing and External Research, Europe, Merck & Co
Karl Naegler, General Partner, Ventech
18.30
DyoDelta European Life Science Innovation Awards Ceremony
presented by
Dimitri Dimitriou, CEO, DyoDelta Biosciences Ltd
18.45
Networking Reception Sponsored by DyoDelta Biosciences
 

 
Agenda
Tuesday 15 September 2009
08.15
Registration & Coffee
09.00
Global Trends Investor Panel
Chair: TBC
Panellists: Raphaël Wisniewski, Partner, Edmond de Rothschild Investment Partners
Christina Takke, Principal, Forbion Capital Partners
Arthur Franken, Partner, Gilde Investment Management B.V.
Jacob Gunterberg, Partner, HealthCap
10.00
Coffee Break
10.15
Company Presentations
Auditorium Room Decision Room
10.15
Addex Pharmaceuticals Cellerix SA
10.30
Axentis Pharma AG tba
10.45
Affimed Cardio3 Biosciences
11.00
Cerimon Pharmaceuticals, Inc tba
11.15
CureVac BIOCRATES Life Sciences AG
11.30
ESBATech AG Galantos Pharma GmbH
11.45
Evolva SA Haemostatix Ltd
12.00
Wilex AG Xention Ltd
12.15
Scil Proteins GmbH Lumavita AG
12.30
Siena Biotech Sensimed AG
12.45
Synosia Therapeutics TcLand Expression S.A.
13.00 - 14.00
Networking Lunch & Close of Conference

 

Back to top